MYND Life Sciences Inc. (MYNDF)
MYND Life Sciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Port Coquitlam, BC, CA. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $657,843. On trailing twelve-month figures it carries a trailing P/E of -2.18, a net margin of 0.0%. Its beta of 0.98 implies it has historically moved less than the broad market.
MYND Life Sciences Inc. operates as a neuro-pharmaceutical company, applying life science principles to develop innovative treatments for depressive conditions. The firm conducts scientific research and clinical trials in Canada and the United States, concentrating on therapeutic compounds that possess neuro-anti-inflammatory properties. A significant part of its research involves the in-depth study of psilocin and psilocybin extracts, along with their various analogs. The company's principal office is situated in Kelowna, Canada.
MYND Life Sciences Inc. is most often compared with the following Healthcare names: